Embla is the only peer-reviewed GLP-1 benefit that brings best-in-class cardiometabolic outcomes while dramatically reducing GLP-1 spend.
Your clients need GLP-1 coverage. But every path on the table right now creates a new problem.
GLP-1s now account for 14% of all Rx spend. Pharmacy costs spike. PBM rebates obscure the real number. 45% of users discontinue within a year and the weight comes back. The spend doesn't.
29% of employees say they'd switch employers for GLP-1 access. Your client loses ground in the talent market and you're the one who has to explain why they didn't act.
84% of consultants report point solution fatigue among their clients. Another vendor, another integration, another login. That's not a recommendation. It's a burden.
Licensed clinician, 1:1 coach, GLP-1 medication, and the member app. Everything in one predictable monthly price per engaged member.
If a member needs more medication, we absorb the cost. Our members average less than half the standard maximum dose. That's our bet to make.
Because the behavioral intervention drives outcomes, members need far less medication. Lower doses mean lower drug cost, fewer side effects, and a realistic path off GLP-1s entirely.
Same criteria, three models. One clear recommendation for your clients.
The behavioral work is the intervention. Medication quiets the noise while members build skills that last. 78.5% taper or stop GLP-1s with no average weight regain.
See the researchSame dedicated coach. CBT and ACT-based. Nutrition, movement, sleep, stress, emotional eating.
Independently prescribed by a licensed clinician. Fewer side effects, less muscle loss, lower cost.
Planned from day one. Gradual, never rushed. 78.5% taper or stop successfully.
Continued coaching, accountability, and habit reinforcement after tapering.
Over 64 weeks. Consistent across BMI classes. Comparable to clinical trial results at a fraction of the medication.
~1.08 mg/week average. Less than half the 2.4 mg standard maximum.
No average weight regain at six months. This is our own published research (Seier et al., Diabetes, Obesity and Metabolism, 2025).
Watch our co-founder walk through an actual employer report: engagement, weight loss, medication usage, tapering, and cost impact. This is what your clients receive quarterly.
You bring the client relationship. We bring a GLP-1 benefit with published outcomes, bundled pricing, and zero plan disruption.
GLP-1 access is a top-3 employee demand. A cost-controlled solution with published outcomes positions you as the advisor who brought the answer.
A fully managed carve-out with bundled pricing and peer-reviewed data is a different conversation than the same PBM-managed approach everyone else recommends.
No plan design changes. No PBM renegotiation. No carrier disruption. If it doesn't work, nothing was touched. If it does, you brought it.
Co-branded materials, client presentations, dedicated partner contact, and outcomes reporting for your reviews. We never go around you.
Sidhartha Sinha
Co-founder, Avant Health
One-pager, comparison table, client FAQ, and study summary. One PDF, one meeting.
The full guide to cost-controlled GLP-1 benefit design. Share it with clients directly.
Two pages. The largest real-world GLP-1 study published. The evidence behind the recommendation.
Talk to Paul about your book of business. He'll walk you through the model, the data, and what it looks like for your clients.
Or email [email protected] directly.
Medical services are provided by independently licensed clinicians, not by Embla Health US Inc. A licensed provider in your state evaluates eligibility for any treatment. Not everyone will qualify. Consultations are delivered via telehealth. Telehealth services may not be available in all states.